| Rank |
Pathway / Axis |
Cancer / Tumor Context |
Normal Tissue Context |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Microtubule stabilization → Mitotic arrest |
Mitotic progression ↓; spindle dynamics impaired; cell division blocked |
Proliferating normal cells affected |
R, G |
Core cytotoxic mechanism |
Binds β-tubulin and stabilizes microtubules, preventing normal depolymerization required for mitosis. |
| 2 |
Spindle assembly checkpoint activation |
Prolonged mitotic arrest → mitotic catastrophe or apoptosis |
Checkpoint stress in dividing tissues |
R, G |
Mitotic stress execution |
Cell fate depends on whether arrest resolves via apoptosis or mitotic slippage. |
| 3 |
Intrinsic apoptosis (mitochondrial pathway) |
Caspase activation ↑; BAX/mitochondrial signaling engaged (context) |
Limited unless stressed |
G |
Cell death execution |
Often downstream of prolonged mitotic stress and mitochondrial perturbation. |
| 4 |
ROS generation (secondary) |
ROS ↑ (context-dependent); oxidative stress amplification |
Oxidative stress possible in sensitive tissues |
R, G |
Stress amplifier |
ROS rise appears secondary to mitotic and mitochondrial dysfunction; may enhance apoptosis. |
| 5 |
Nrf2 antioxidant response (adaptive) |
Nrf2 ↑ in some tumors; antioxidant buffering ↑; resistance potential |
Protective antioxidant signaling |
G |
Adaptive resistance axis |
Not a direct paclitaxel target; elevated Nrf2 may reduce drug sensitivity. |
| 6 |
Drug resistance mechanisms |
P-glycoprotein (MDR1) ↑; β-tubulin alterations; survival rewiring |
— |
G |
Treatment failure driver |
Efflux pumps and tubulin adaptations are major clinical resistance mechanisms. |
| 7 |
Myelosuppression |
— |
Neutropenia risk ↑ |
G |
Dose-limiting toxicity |
Bone marrow suppression is a primary clinical constraint. |
| 8 |
Peripheral neuropathy |
— |
Sensory neuropathy risk ↑ |
G |
Dose-limiting toxicity |
Likely related to microtubule disruption in axonal transport. |